Related Experiment Video
Updated: Jun 13, 2026

Challenges in Rheological Characterization of Highly Concentrated Suspensions — A Case Study for Screen-printing Silver Pastes
Published on: April 10, 2017
In vitro/in vivo and analytical evaluation of sunless tanning formulations containing different rheology modifiers
Olga V Dueva-Koganov1, Yamini Mandalia, Juan Brito
1Ciba Corporation (Part of BASF Group), Tarrytown, NY, USA.
Abstract:
In vitro data suggest that different in vivo performances are expected for two dihydroxyacetone (DHA)-containing formulations with similar concentrations of DHA and excipients but different commercially available rheology modifiers: one with a cationic polymer-based rheology modifier (blend) [dimethylacrylamide/ethyltrimonium chloride methacrylate copolymer (and) propylene glycol dicaprylate/dicaprate (and) PPG-1 trideceth-6 (and) C10-11 isoparaffin]; and the other with a polyacrylamide-based rheology modifier (blend) [polyacrylamide (and) C13-14 isoparaffin (and) laureth-7]. Both rheology modifiers (blends) contained comparable levels of polymers and were used at 3% w/w (as supplied). Differences in color development were illustrated in vitro with respect to the yellow/red and lightness/chroma parameters, which were confirmed in the followup in vivo studies. The test article with the cationic polymer-based rheology modifier produced a more natural sunless tan, comparable to a desirable sun-induced tan, for all panelists, one that was more uniform and lasted longer compared with the sunless tan generated by the test article with the polyacrylamide-based rheology modifier. A method for HPLC analysis of DHA in sunless tanning formulations was established and utilized to confirm concentrations of DHA in test articles.
Related Concept Videos
In Vitro Drug Dissolution: Alternative Methods
In Vitro Drug Dissolution: Compendial Testing Models II
In Vitro Drug Dissolution: Compendial Testing Models I
In Vitro Drug Release Testing: Overview, Development and Validation
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

